Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China flag China · Delayed Price · Currency is CNY
4.420
-0.190 (-4.12%)
At close: Jul 30, 2026

SHA:688373 Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
150.62141.77130.2790.7848.217.66
Revenue Growth
15.44%8.83%43.51%88.31%529.33%-
Gross Profit
128.17120.24107.8774.0839.386.9
Operating Income
-205.48-247.21-438.66-439.98-257.52-269.3
Net Income
-201.43-241.61-440.72-421.12-220.3-226.27
Earnings Per Share
-0.30-0.37-0.67-0.64-0.38-0.43
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
420.86451.64593.62953.31,270471.88
Total Debt
370.97379.62301.86221.19230.21160.99
Net Cash (Debt)
49.972.02291.76732.111,040310.88
Net Cash Growth
-79.44%-75.32%-60.15%-29.60%234.52%-50.69%
Net Cash Per Share
0.080.110.441.121.790.59

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-174.14-210.18-447.18-329.08-240.01-180.98
Capital Expenditures
-0.55-0.55-0.91-7.66-12.18-22.91
Free Cash Flow
-174.69-210.73-448.1-336.74-252.18-203.89
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
85.10%84.81%82.80%81.61%81.70%90.08%
Operating Margin
-136.43%-174.37%-336.72%-484.69%-534.19%-3515.62%
Pretax Margin
-136.35%-173.21%-333.54%-457.34%-456.98%-2953.41%
Profit Margin
-133.74%-170.42%-338.31%-463.91%-456.99%-2953.91%
FCF Margin
-115.99%-148.64%-343.97%-370.96%-523.13%-2661.81%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
19.2627.9324.8547.13120.42-